Legal Action and Patent Infringement - BioMarin Pharmaceutical Inc has initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany [1] - The patent covers long-acting variants of C-Type Natriuretic Peptide (CNP) [1] - The legal action is based on BioMarin's belief that Ascendis' TransCon CNP investigational product and its development program in Germany and elsewhere in Europe infringe BioMarin's patent [2] - The BioMarin patent was confirmed by the European Patent Office's Opposition Division in 2024 [2] Unified Patent Court (UPC) Jurisdiction - The UPC, which formally started in June 2023, has jurisdiction over European patents for 18 European member states that have ratified the Unitary Patents (UPs) [3] - These member states include Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Portugal, Romania, Slovenia, and Sweden [3] Company Background and Commitment - BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient [4] - The company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline [4] - BioMarin is committed to protecting the important inventions its scientists make for patients around the world, including the more than 15 years of scientific research that supported VOXZOGO® and BMN 333, its long-acting CNP [4] Trademarks and Contacts - BioMarin® and VOXZOGO® are registered trademarks of BioMarin Pharmaceutical Inc [6] - Contacts for investors and media are Traci McCarty and Andrew Villani, respectively [7]

Stock Performance and Price Targets - BioMarin Pharmaceutical (BMRN) shares have gained 2.1% over the past four weeks, closing at $67.38 [1] - The mean price target estimate of $98.28 indicates a potential upside of 45.9% [1] - The average price target comprises 25 estimates ranging from $65 to $138, with a standard deviation of $17.42 [2] - The lowest estimate suggests a 3.5% decline, while the most optimistic estimate points to a 104.8% upside [2] Analyst Consensus and Earnings Estimates - Strong agreement among analysts about the company's ability to report better earnings strengthens the view of a potential upside [4] - The Zacks Consensus Estimate for the current year has increased 4.3% over the past month, with one positive revision and no negative revisions [10] - BMRN currently holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks [11] Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets to generate interest in companies with which their firms have business relationships [6] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts [7] - Empirical research shows that price targets rarely indicate where a stock's price is actually heading [5] Investment Considerations - While price targets should not be entirely ignored, making investment decisions solely based on them could lead to disappointing returns [8] - The direction of price movement implied by the consensus price target appears to be a good guide, even if the target itself is not reliable [12]

SAN RAFAEL, Calif., Jan. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 43rd Annual J.P. Morgan Conference on Monday, January 13, 2024, at 9:00 am PT / 12:00 pm ET, in San Francisco, California. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available thro ...

Investors in BioMarin Pharmaceutical Inc. (BMRN) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $40 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It c ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores a ...

A month has gone by since the last earnings report for BioMarin Pharmaceutical (BMRN) . Shares have lost about 1.9% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is BioMarin due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Q3 Earnings & Sales Top EstimatesBioMarin r ...

BioMarin Pharmaceutical TodayBMRNBioMarin Pharmaceutical$63.44 +0.88 (+1.41%) 52-Week Range$61.15▼$99.56P/E Ratio37.99Price Target$94.20Add to WatchlistBioMarin Pharmaceutical NASDAQ: BMRN has been a rough investment for a long time. Over the past 10 years, shares have provided a total return of -28%. However, Wall Street analysts have consistently given this stock price targets that are much higher than its trading price. They see more fundamental value in the company than the market will give it credit f ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.I last covered BioMarin (NASDAQ: BMRN ) in a note for Seeking Alpha back in June last year, just ahead of the Prescription Drug User fee Act ("PDUFA") date for its hemophil ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...

UBS Global Healthcare Conference on November 12 at 11:00 am PST Jefferies London Healthcare Conference on November 19 at 9:00 am GMT 7th Annual Evercore ISI HealthCONx Conference on December 4 at 7:00 am PSTSAN RAFAEL, Calif., Nov. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences.An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An ...